Medicine & Healthcare

A 68% Cure Rate Against Superbugs Proves We Can Solve Problems We Choose to Solve

Shionogi presented real-world data at ESCMID Global 2026 showing cefiderocol (Fetroja/Fetcroja) achieved a 68% clinical cure rate at day 14 and 83% survival at day 28 in patients with MBL-producing Enterobacterales infections. The CIRCE study covered 232 patients across Spanish hospitals. AMR kills 1.27 million people annually, yet antibiotic R&D receives a fraction of oncology funding.